CTOs on the Move

Genesys Spine

www.genesysspine.com

 
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.genesysspine.com
  • 1250, South Capital of Texas Highway
    Austin, TX USA 78746
  • Phone: 512.381.7070

Executives

Name Title Contact Details

Similar Companies

Consumer Healthcare Products Association

Founded in 1881, the Consumer Healthcare Products Association (CHPA) is the national trade association representing the leading manufacturers and marketers of over-the-counter (OTC) medicines, dietary supplements, and consumer medical devices. Every dollar spent by consumers on OTC medicines saves the U.S. healthcare system $6-$7, contributing a total of $102 billion in savings each year. CHPA is committed to promoting the increasingly vital role of OTC medicines and dietary supplements in America`s healthcare system through science, education, and advocacy.

North Bend Medical Center

NBMC is a multi-specialty, regional medical center with more than 400 employees and 70 medical providers representing approximately 20 specialties

SpaLab

SpaLab, Inc. is a San Marcos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Focus Express Mail Pharmacy Inc

Focus Express Mail Pharmacy Inc is a Horsham, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Immunic

Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn`s disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.